AZU-101 for Genitourinary Syndrome

This trial tests a new treatment called AZU-101 (Lasofoxifene Tartrate) for postmenopausal women with genitourinary syndrome, which can cause pain during sexual activity. Researchers aim to determine the treatment's safety, how the body processes it, and its effectiveness in improving vaginal health. Participants will receive either a low dose of the treatment or a placebo for 14 days. Women who are postmenopausal, have had no periods for at least three years, and experience pain during sex may be suitable candidates for this trial. As a Phase 2 trial, the research focuses on evaluating the treatment's effectiveness in an initial, smaller group of participants.

Participants must stop using certain hormone-related medications and supplements before joining the trial. Specifically, oral, transdermal, and vaginal hormone products, as well as certain supplements, must be stopped for a specified period before the screening visit. If you are taking a statin, you must be on a stable dose for 3 months before and during the study.

Studies have shown that lasofoxifene tartrate is generally well-tolerated. In earlier research, participants taking oral lasofoxifene experienced significant improvements in vaginal symptoms such as dryness and discomfort. However, most studies so far have been observational, and more information about long-term safety is still needed.

In two large studies, oral lasofoxifene provided meaningful benefits without major side effects reported. This suggests it is likely safe, but additional data from ongoing research will help confirm its long-term safety.

Most treatments for genitourinary syndrome focus on hormone replacement or local estrogen therapy. However, lasofoxifene tartrate offers a novel approach by using a selective estrogen receptor modulator (SERM). Unlike traditional hormone therapies, this drug specifically targets estrogen receptors in the vaginal tissue, potentially reducing side effects associated with systemic hormone treatments. Researchers are excited because lasofoxifene tartrate is administered vaginally, promising a localized effect that could provide relief within just 14 days. This targeted delivery method may offer a faster and more focused treatment option compared to existing therapies.

Research has shown that lasofoxifene tartrate can significantly improve symptoms of genitourinary syndrome in postmenopausal women. Studies have found that oral lasofoxifene helps with vaginal health issues, such as dryness and discomfort. Specifically, doses of 0.25 mg/day and 0.5 mg/day effectively eased these symptoms. The treatment also improved overall vaginal health in postmenopausal women. These findings suggest that lasofoxifene could be a promising option for managing these symptoms in this group. In this trial, participants will receive either a 1 microgram dose of lasofoxifene tartrate or a placebo, administered vaginally for 14 days, to evaluate its effectiveness in treating genitourinary syndrome.¹²³⁴⁶